The clustering of hyperinsulinaemia, impaired glucose intolerance, dyslipidaemia, hypertension and obesity is characteristic of the metabolic syndrome. There are two main classifications of the metabolic syndrome, the World Health Organization (WHO) 3 and the National Cholesterol Education Program and Treatment of High Blood Cholesterol in Adults Panel (NCEP/ATPIII). 4 The WHO definition requires evidence of insulin resistance and therefore an oral glucose tolerance test; however, the NCEP ATP III definition is more pragmatic and developed to be used in clinical practice. Both of these classifications predict type II diabetes, cardiovascular disease and cardiovascular mortality. 5, 6 As stated in Chatterjee's paper, early unexplained mortality in adult recipients of BMT has raised concerns regarding accelerated cardiovascular risk in this group of patients. Case reports describe early cardiovascular morbidity in adults following successful childhood bone marrow transplantation. 7 Until recently the metabolic sequelae of BMT in adults remained unknown.
In our abstract, we described 16 patients seen at first visit in a combined Haematology/Metabolic Medicine Late Effects clinic. Of 16 patients (10 male: six female), mean age 38 (25-54) year, mean time from transplant 6 (1-12) year, 79% allograft, 21% autograft, 93% had received total body irradiation (TBI). Two had received oral steroid treatment in the previous year but had stopped for atleast 3 months.
According to WHO criteria, 47% of the patients had central obesity, 63% had hypertriglyceridaemia, 33% had low HDL cholesterol, 20% were hypertensive, 27% had an elevated albumin:creatinine ratio and 13% had abnormal glucose metabolism. One patient had impaired glucose tolerance (IGT), another type II diabetes. The prevelance of the metabolic syndrome as defined by WHO and/or NCEP ATP III criteria was 25%. In addition, two patients had steroid-induced diabetes at transplantation, which resolved on cessation of steroid treatment. This could be considered to be a marker of insulin resistance. Both of these patients also had two other features of metabolic syndrome and so although not strictly fulfilling the WHO criteria could be described as likely to have metabolic syndrome. One of these subjects has subsequently (within 1year) developed IGT.
Chatterjee et al raise some important issues particularly the potential metabolic consequences of BMT. Our observational report shows that features of the metabolic syndrome are common in patients who have had BMT in adulthood. These are preliminary observations and further work is necessary to determine the true prevelance of the metabolic syndrome in this group of patients.
The metabolic syndrome is an important emerging area. There has been recent focus on early intervention strategies to prevent cardiovascular morbidity. In high risk individuals with type II diabetes there is evidence that targeted intensified multifactorial intervention can reduce cardiovascular events by 50%.
8 It has been shown in the metabolic syndrome that lifestyle intervention (exercise, dietary changes) can reduce insulin resistance and delay onset of diabetes in those with IGT.
9,10 No studies to date address multirisk factor intervention in the metabolic syndrome or the effects this may have on cardiovascular outcomes. Currently, we do not know if intervention with lifestyle changes combined with lipid lowering therapy, blood pressure control and antiplatelet therapy in subjects with metabolic syndrome will reduce mortality. Some of these questions may be addressed by large multicentre studies in progress investigating the effect of multiple interventions in subjects with metabolic syndrome.
Clearly large prospective trials are required in the evergrowing population of adults who have received BMT We have read the comments of Higgins et al with great interest and we were pleased to learn that they substantiated our findings of metabolic syndrome in another cohort of female BMT recipients. We were unaware of their observations as at the time of writing the paper their paper was not indexed in Pubmed.
We have previously reported the evidence of cavernosal arterial insufficiency in male BMT recipients.
1,2 Recently, we published a case report of a BMT recipient who presented with erectile dysfunction and cavernosal arterial insufficiency in support of the vasulogenic theory of metabolic syndrome.
